<!DOCTYPE html>
<html lang="en" dir="ltr">
  <head>
    <meta charset="utf-8">
    <title>HCP Home</title>
    <link rel="stylesheet" href="styles.css">
    <style>
    .creative1 {
      background-image: url("images/capsuleclaim.jpg");
      color: white;
      text-align: center;
      font-size: 30px;
      height: 275px;
      background-repeat: no-repeat;
          }

      .creative2 {
        background-image: url("images/rocket.JPG");
        background-repeat: no-repeat;
        max-width: 1000px;
        height:300px;
        margin: auto;
      }



    </style>
  </head>
  <body>

        <p style="font-family: impact; display: inline; color: purple; font-size: 25px;">Energon<sup style="color: black; font-size: 14px;">TM</sup></p>
    <a href="constructionEn.html" style="float: right; margin: 5px">Medical Info Access   </a>
    <a href="index.html" style="float: right; margin: 5px">   Logout   </a>
    <a href="constructionFr.html" style="float: right; margin: 5px">   French</a>
    <br>
    <br>
    <ul class="nav">
      <li class="nav"><a class="active" href="hcphome.html">Home</a></li>
      <li class="nav"><a href="tech.html">LFHC technology</a></li>
      <li class="nav"><a href="MOA.html">MOA</a></li>
      <li class="nav"><a href="studies.html">Studies</a></li>
      <li class="nav"><a href="dosing.html">Dosing</a></li>
      <li class="nav"><a href="safety.html">Safety Info</a></li>
    </ul>
<!--
    <div class="creative1">
      <h2>Energize with Energon</h2>
    </div>
-->

    <div class="creative2">
      <h1 style="color: white;">Efficacy for the symptoms of MDD</h1>
    </div>

<!--
    <h3>Energon has the power to <span style="color: red;">break</span> your patients <span style="color: red;">out</span> of the depression cycle.</h3>
-->
    <!-- power that is out of this world-->

	<p>ENERGON is indicated for the symptomatic relief of MDD.</p>
    


    <br>
<!--
<p style="text-decoration: underline; font-weight: bold;">Indications and Clinical Use:</p>
<p>ENERGON is indicated for the symptomatic relief of MDD.<br><br>
ENERGON is not indicated for use in children under the age of 18.<br><br>
The short-term efficacy of ENERGON has been demonstrated in placebo-controlled trials of up to 8 weeks.<br><br>
The efficacy of ENERGON in maintaining an antidepressant response for up to 26 weeks, following response during 20 weeks of acute, open-label treatment, was demonstrated in a placebo-controlled trial.</p>

<p style="text-decoration: underline; font-weight: bold;">Contraindications:</p>
<ul>
<li>Concomitant use with monoamine oxidase inhibitors (MAOIs) or within the preceding 14 days.</li>
<li>Hypersensitivity to venlafaxine hydrochloride</li>
</ul>

<p style="text-decoration: underline; font-weight: bold;">Most Serious Warnings and Precautions:</p>
<p><span style="font-weight: bold;">Behavioural and emotional changes, including self-harm:</span> SSRIs and other newer antidepressants may be associated with:</p>
<ul>
<li>Behavioural and emotional changes including and increased risk of suicidal ideation and behaviour</li>
<li>Severe agitation-type adverse events coupled with self-harm or harm to others</li>
<li>Suicidal ideation and behavior; rigorous monitoring</li>
</ul>

<p><span style="font-weight: bold;">Discontinuation symptoms:</span> should not be discontinued abruptly. Gradual dose reduction is recommended.</p>


<p style="text-decoration: underline; font-weight: bold;">Other Relevant Warnings and Precautions:</p>
<ul>
<li>Concomitant use with venlafaxine not recommended</li>
<li>Allergic reactions such as rash, hives or a related allergic phenomenon</li>
<li>Bone fracture risk</li>
<li>Increases in blood pressure and heart rate (measurement prior to and regularly during treatment)</li>
<li>Increases cholesterol and triglycerides (consider measurement during treatment)</li>
<li>Hyponatremia or Syndrome of Inappropriate Antidiuretic Hormone (SIADH)</li>
<li>Potential for GI obstruction</li>
<li>Abnormal bleeding</li>
<li>Interstitial lung disease and eosinophilic pneumonia</li>
<li>Seizures</li>
<li>Narrow angle glaucoma</li>
<li>Mania/hypomania</li>
<li>Serotonin syndrome or neuroleptic malignant syndrome-like reactions</li>
</ul>

<p style="text-decoration: underline; font-weight: bold;">For More Information:</p>
<p>Please <a href="images/PM.pdf">CLICK HERE</a> to consult the Product Monograph for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.</p>
-->

    <div class="footer-left">
      <p><span style="font-family: impact; font-size: 30px; color: blue;">B</span><span style="font-size: 25px">itMED</span><sup style="color: black; font-size: 14px; font-family: impact;">TM</sup><br>
      Applying Blockchain to Medicine</p>
    </div>

    <div class="footer-right">
      <p style="font-family: impact; color: purple; font-size: 25px;">Energon<sup style="color: black; font-size: 16px;">Rx</sup><br>
      <span style="font-family: arial; font-size: 15px; color: black; vertical-align: text-top;">Levodognacipran</p>

    </div>

  </body>
</html>
